Glucagon Receptor

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

Tirzepatide (LY-3298176) is a dual agonist of glucose-dependent polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor with neuroprotective activity for the study of diabetes and obesity.

Tirzepatide (LY3298176) Acetate (2023788-19-2 free base) is a new molecule that can control blood glucose levels by combining dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[3]

Tirzepatide sodium salt (LY3298176 sodium salt) is a GIP and GLP-1 receptor agonist with neuroprotective activity and can be used to treat obesity.

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

LSN3318839 is a potent and orally available glucagon-like peptide-1 receptor (GLP-1R) modulator.LSN3318839 enhances GLP-1R G-protein-coupled signaling and can be used to lower blood glucose.

GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).

Avexitide (Exendin-3 (9-39) amide) (Exendin (9-39)) is a specific and competitive antagonist of glucagon-like peptide-1 (GLP-1) receptor.

Exendin-4 (Exenatide) is a glucagon-like peptide-1 receptor (GLP-1) agonist (IC50: 3.22 nM). Exenatide is a 39 amino acid peptide. Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.

Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.

MK-0626 is an orally available dipeptidyl peptidase IV (DPP-4) inhibitor that attenuates hepatic steatosis and accumulation by enhancing AMPK activity.MK-0626 attenuates TAC-induced diabetic pancreatic islet injury by restoring the expression of GLP-1R.MK-0626 is able to increase circulating endothelial progenitor cell numbers and endothelial-type nitric oxide synthase expression by promoting neoangiogenesis.

Exenatide (Extendin-4) is a glucagon-like protein-1 (GLP-1) receptor agonist.

Exendin-4 acetate is a 39 amino acid peptide.Exendin-4 acetate is a long-acting GLP-1 receptor agonist(IC50 = 3.22 nM).

Glucagon (1-29), bovine, human, porcine hydrochloride (Porcine glucagon hydrochloride) is a peptide hormone produced by pancreatic α-cells that activates HNF4α, increases HNF4α phosphorylation, and stimulates gluconeogenesis.

Cotadutide acetate (MEDI0382 acetate) is a potent peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptor with EC50 of 6.9 pM and 10.2 pM, respectively.

Orforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults.

Volagidemab (AMG-477) is a glucagon receptor (GCGR) antagonist and monoclonal antibody for the study of endocrine and metabolic diseases such as type 1 diabetes (T1D) and hypoglycemia.

GLP-1(7-36), amide acetate is a derivative of GLP-1 peptide (glucagon-like peptide-1).GLP-1(7-36), amide is able to activate the GLP-1 receptor, which has the ability to promote insulin secretion and inhibit glucagon secretion, with the potential to treat type 2 diabetes mellitus and obesity.

Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.

GRA Ex-25 (GRA-Ex-25) is an inhibitor of glucagon receptor.

Bay 55-9837 acetate is a potent and highly selective VPAC2 agonist(Kd = 0.65 nM) and can be used in type 2 diabetes studies.

PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist.

antagonist at the human GLP-1 receptor